{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:34:20Z","timestamp":1791041660352,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":961,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF), which is caused by wide various conditions, has become a major public health problem. Transthyretin amyloid cardiomyopathy (ATTR-CM), which is thought to be an underdiagnosed disease, can cause HFpEF. Non-invasive diagnosis using 99mTechnetium (Tc)-pyrophosphate (PYP) scintigraphy enables accurate diagnosis of ATTR-CM. The aim of this study was to clarify the prevalence and characteristics of ATTR-CM among Japanese patients with HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This study was a multicentre, prospective, observational study conducted in Japan. We enrolled 373 patients with HFpEF [left ventricular (LV) ejection fraction \u226550%] aged \u226565 years who were admitted to the department of cardiology from September 2018 to January 2022. A 99mTc-PYP scintigraphy scan was performed during admission in all eligible patients. Cardiac 99mTc-PYP retention was graded according to a previously reported visual scale ranging from 0 to 3 points. The scan was considered positive when it revealed moderate-to-severe 99mTc-PYP uptake (Grade 2\u20133) in both ventricles. Patients were divided into ATTR-CM and non-ATTR-CM patients according to positive (Grade 2\u20133) or negative (Grade 0\u20131) 99mTc-PYP scintigraphy, respectively. Medical history, blood tests, electrocardiogram, echocardiography, and magnetic resonance imaging in the two groups of patients were compared. Among the 373 patients with HFpEF, 53 patients (14.2%; 95% confidence interval: 10.7\u201317.7) showed positive uptake on 99mTc-PYP scintigraphy. An endomyocardial biopsy was performed in 32 patients and confirmed amyloidosis in all cases. There were no significant differences between the two groups in age, severity of heart failure as assessed by the New York Heart Association (NYHA) functional classification, renal function values, left ventricular ejection fraction, and tricuspid regurgitant pressure gradient (ATTR-CM, n = 53 vs. non-ATTR-CM, n = 320). Patients in the ATTR-CM group had a higher N-terminal pro-brain natriuretic peptide level [2314 (1081\u20133398) vs. 900 (415\u20131828), P &amp;lt; 0.001], higher sensitive troponin T level (0.074 \u00b1 0.049 vs. 0.035 \u00b1 0.038, P &amp;lt; 0.001), and higher mean LV maximal wall thickness [12.5 (11\u201314) vs. 10.5 (9.5\u201311.5), P &amp;lt; 0.001].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ATTR-CM is an underdiagnosed disease with a significant prevalence in Japanese patients with HFpEF. This study showed that results of examinations for ATTR-CM patients appear to be worse than those for non-ATTR-CM patients, but clinical severities of heart failure as assessed by the NYHA functional classification are similar in ATTR-CM and non-ATTR-CM patients, and the clinical overlap between ATTR-CM and non-ATTR-CM is high.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14364","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T03:49:30Z","timestamp":1679888970000},"page":"1896-1906","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prevalence of Transthyretin Amyloidosis Among Heart Failure Patients with Preserved Ejection Fraction in Japan"],"prefix":"10.1093","volume":"10","author":[{"given":"Takanori","family":"Naito","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-3626","authenticated-orcid":false,"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka City General Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Bay Urayasu Ichikawa Medical Center , Urayasu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Sakuragi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center , Iwakuni ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center , Iwakuni ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kihara Cardiovascular Clinic , Asahikawa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsutaka","family":"Okizaki","sequence":"additional","affiliation":[{"name":"Department of Radiology, Asahikawa Medical University , Asahikawa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama City Hospital , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukuyama City Hospital , Fukuyama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takaishi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mitoyo General Hospital , Kanonji ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujio","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Japanese Red Cross Society Himeji Hospital , Himeji ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center , Iwakuni ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]},{"name":"Department of Cardiology, IMS Katsushika Heart Center , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ATTR-HFpEF registry investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"2026012114095643500_ehf214364-bib-0001","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur Heart J"},{"key":"2026012114095643500_ehf214364-bib-0002","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/eurheartj\/ehu067","article-title":"Heart failure with preserved ejection fraction: a clinical dilemma","volume":"35","author":"Komajda","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012114095643500_ehf214364-bib-0003","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ehf2.13110","article-title":"Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic","volume":"8","author":"Lindmark","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114095643500_ehf214364-bib-0004","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"2026012114095643500_ehf214364-bib-0005","first-page":"23","article-title":"Molecular mechanisms of cardiac amyloidosis","volume":"23","author":"Saito","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026012114095643500_ehf214364-bib-0006","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114095643500_ehf214364-bib-0007","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2967\/jnumed.120.245381","article-title":"Molecular imaging of cardiac amyloidosis","volume":"61","author":"Masri","year":"2020","journal-title":"J Nucl Med"},{"key":"2026012114095643500_ehf214364-bib-0008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026012114095643500_ehf214364-bib-0009","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehv328","article-title":"Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction","volume":"36","author":"Castano","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114095643500_ehf214364-bib-0010","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114095643500_ehf214364-bib-0011","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/ehf2.13473","article-title":"Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm","volume":"8","author":"Inomata","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114095643500_ehf214364-bib-0012","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCIMAGING.113.001396","article-title":"How to image cardiac amyloidosis","volume":"7","author":"Falk","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012114095643500_ehf214364-bib-0013","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution","volume":"14","author":"Poterucha","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114095643500_ehf214364-bib-0014","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012114095643500_ehf214364-bib-0015","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"69","author":"Ponikowski","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026012114095643500_ehf214364-bib-0016","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0002-8703(49)90562-1","article-title":"The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads","volume":"37","author":"Sokolow","year":"1949","journal-title":"Am Heart J"},{"key":"2026012114095643500_ehf214364-bib-0017","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012114095643500_ehf214364-bib-0018","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.cardfail.2019.08.002","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization","volume":"25","author":"Dorbala","year":"2019","journal-title":"J Card Fail"},{"key":"2026012114095643500_ehf214364-bib-0019","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","article-title":"Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis","volume":"25","author":"Bokhari","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"2026012114095643500_ehf214364-bib-0020","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012114095643500_ehf214364-bib-0021","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archinte.1987.00370060035007","article-title":"Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis","volume":"147","author":"Gertz","year":"1987","journal-title":"Arch Intern Med"},{"key":"2026012114095643500_ehf214364-bib-0022","first-page":"160","article-title":"Congo red overlay immunohistochemistry aids classification of amyloid deposits","volume":"1999","author":"Tennent","year":"1998","journal-title":"Amyloid Amyloidosis"},{"key":"2026012114095643500_ehf214364-bib-0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"Authors\/Task Force Members","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114095643500_ehf214364-bib-0024","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJMc1814074","article-title":"Tafamidis for transthyretin amyloid cardiomyopathy","volume":"380","author":"Maurer","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114095643500_ehf214364-bib-0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"key":"2026012114095643500_ehf214364-bib-0026","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3181\/00379727-156-39920","article-title":"Localization of 99mTc-labeled pyrophosphate and calcium in mycoardial infarcts after temporary coronary occlusion in dogs","volume":"156","author":"Reimer","year":"1977","journal-title":"Proc Soc Exp Biol Med"},{"key":"2026012114095643500_ehf214364-bib-0027","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","article-title":"Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis","volume":"25","author":"Stats","year":"2016","journal-title":"Cardiovasc Pathol"},{"key":"2026012114095643500_ehf214364-bib-0028","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010249","article-title":"Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis","volume":"13","author":"Masri","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012114095643500_ehf214364-bib-0029","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s12350-020-02205-1","article-title":"Tc-99m-pyrophosphate scintigraphy for the diagnosis of ATTR cardiac amyloidosis: comparison of quantitative and semi-quantitative approaches","volume":"27","author":"Regis","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026012114095643500_ehf214364-bib-0030","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026012114095643500_ehf214364-bib-0031","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar Technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012114095643500_ehf214364-bib-0032","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114095643500_ehf214364-bib-0033","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","article-title":"Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population","volume":"270","author":"Mohamed-Salem","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026012114095643500_ehf214364-bib-0034","first-page":"39","article-title":"Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction","volume":"8","author":"Ton","year":"2014","journal-title":"Clin Med Insights Cardiol"},{"key":"2026012114095643500_ehf214364-bib-0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026012114095643500_ehf214364-bib-0036","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000416","article-title":"Myocardial damage detected by late gadolinium enhancement cardiovascular magnetic resonance is associated with subsequent hospitalization for heart failure","volume":"2","author":"Wong","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026012114095643500_ehf214364-bib-0037","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001808","article-title":"Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis","volume":"9","author":"Slivnick","year":"2022","journal-title":"Open Heart"},{"key":"2026012114095643500_ehf214364-bib-0038","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","article-title":"Non-peptide arginine\u2013vasopressin antagonists: the vaptans","volume":"371","author":"Decaux","year":"2008","journal-title":"Lancet"},{"key":"2026012114095643500_ehf214364-bib-0039","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00380-021-01957-1","article-title":"Clinical features and long-term prognosis of patients with congestive heart failure taking tolvaptan: a comparison of patients with preserved and reduced left ventricular ejection fraction","volume":"37","author":"Seki","year":"2022","journal-title":"Heart Vessels"},{"key":"2026012114095643500_ehf214364-bib-0040","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam","year":"2019","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/1896\/65017981\/eschf_10_3_1896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/1896\/65017981\/eschf_10_3_1896.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:10:52Z","timestamp":1769022652000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/3\/1896\/8304666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,27]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14364","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"2022-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}